Literature DB >> 12970151

Complete regression of advanced HCC with long acting octreotide.

J T Siveke, C Herberhold, C Folwaczny.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12970151      PMCID： PMC1773832          DOI： 10.1136/gut.52.10.1531-a

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

1.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Authors:  E Kouroumalis; P Skordilis; K Thermos; A Vasilaki; J Moschandrea; O N Manousos
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

2.  Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

Authors:  N Benali; P Cordelier; D Calise; P Pages; P Rochaix; A Nagy; J P Esteve; P M Pour; A V Schally; N Vaysse; C Susini; L Buscail
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

3.  Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.

Authors:  J C Reubi; B Waser; J C Schaer; J A Laissue
Journal:  Eur J Nucl Med       Date:  2001-07

4.  Regulatory peptide receptors in human hepatocellular carcinomas.

Authors:  J C Reubi; A Zimmermann; S Jonas; B Waser; P Neuhaus; U Läderach; B Wiedenmann
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

5.  A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

Authors:  Man-Fung Yuen; Ronnie Tung-Ping Poon; Ching-Lung Lai; Sheung-Tat Fan; Chung-Mau Lo; Ka-Wah Wong; Wai Man Wong; Benjamin Chun-Yu Wong
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425
  5 in total
  8 in total

1.  Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.

Authors:  G Treiber; T Wex; C Röcken; P Fostitsch; P Malfertheiner
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

2.  Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide.

Authors:  Liyun Yuan; Jeff Wang; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

Review 3.  Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken.

Authors:  Dimitrios N Samonakis; George Notas; Nikolaos Christodoulakis; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2008-02-14       Impact factor: 3.199

4.  Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.

Authors:  D Dimitroulopoulos; D Xinopoulos; K Tsamakidis; A Zisimopoulos; E Andriotis; D Panagiotakos; A Fotopoulou; C Chrysohoou; A Bazinis; D Daskalopoulou; E Paraskevas
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

Review 5.  Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.

Authors:  Saad Shaaban; Amr Negm; Elsayed E Ibrahim; Ahmed A Elrazak
Journal:  Oncol Rev       Date:  2014-05-28

Review 6.  Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma.

Authors:  Argyrios Periferakis; Georgios Tsigas; Aristodemos-Theodoros Periferakis; Ioana Anca Badarau; Andreea-Elena Scheau; Mircea Tampa; Simona Roxana Georgescu; Andreea Cristiana Didilescu; Cristian Scheau; Constantin Caruntu
Journal:  Anal Cell Pathol (Amst)       Date:  2021-11-27       Impact factor: 2.916

Review 7.  The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.

Authors:  Claudia Pivonello; Maria Cristina De Martino; Mariarosaria Negri; Gaia Cuomo; Federica Cariati; Francesco Izzo; Annamaria Colao; Rosario Pivonello
Journal:  Infect Agent Cancer       Date:  2014-08-20       Impact factor: 2.965

8.  Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.

Authors:  Lynn G Feun; Medhi Wangpaichitr; Ying-Ying Li; Deukwoo Kwon; Stephen P Richman; Peter J Hosein; Niramol Savaraj
Journal:  J Hepatocell Carcinoma       Date:  2018-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.